Sign On | Letter of Thanks to Congress for Introducing Viral Hepatitis Testing Act
Learn more:
Last Updated on July 24, 2023 by HepFree NYC
Tags: Sign On LetterA network building capacity to prevent, manage and treat hepatitis B and C in NYC
Learn more:
Last Updated on July 24, 2023 by HepFree NYC
Tags: Sign On LetterOn February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
The primary goals of the Manual are to increase advocates' knowledge about available HCV tests and treatments and to jumpstart discussions on advocacy strategies that can be used to open up affordable access for more people with HCV.
The NYS Drug Utilization Review Board voted to eliminate most restrictions on prescribing hepatitis C medications for all Medicaid fee-for-service patients.
The Hepatitis A, B and C in NYC: 2021 Annual Report provides the latest surveillance and programmatic data on viral hepatitis in NYC.
Ask your US House Representative to sign onto a House letter requesting additional funding for the Division of Viral Hepatitis at the CDC.
Urge your members of congress to sign on in support of increased funding for the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (CDC) in FY2014. Members of Congress need to know that viral hepatitis is a concern in their district, that their constit...
Sign on Letter | NYS Medicaid Solvaldi Clinical Criteria Comments (Project Inform) The draft clinical criteria for the use of Sofosbuvir (Sovaldi) under NY State Medicaid is open for public comment. See the details of the comment period and clinical criteria here. Project Inform,...
This Consensus statement was adopted at the NYS Hep C Elimination Summit and provides a statewide plan to eliminate Hep C.